These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

952 related articles for article (PubMed ID: 16163262)

  • 1. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
    Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
    Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW
    Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.
    Hicks LA; Harrison LH; Flannery B; Hadler JL; Schaffner W; Craig AS; Jackson D; Thomas A; Beall B; Lynfield R; Reingold A; Farley MM; Whitney CG
    J Infect Dis; 2007 Nov; 196(9):1346-54. PubMed ID: 17922399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevenar vaccination: review of the global data, 2006.
    Center KJ
    Vaccine; 2007 Apr; 25(16):3085-9. PubMed ID: 17287048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.
    Byington CL; Samore MH; Stoddard GJ; Barlow S; Daly J; Korgenski K; Firth S; Glover D; Jensen J; Mason EO; Shutt CK; Pavia AT
    Clin Infect Dis; 2005 Jul; 41(1):21-9. PubMed ID: 15937758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
    Pilishvili T; Lexau C; Farley MM; Hadler J; Harrison LH; Bennett NM; Reingold A; Thomas A; Schaffner W; Craig AS; Smith PJ; Beall BW; Whitney CG; Moore MR;
    J Infect Dis; 2010 Jan; 201(1):32-41. PubMed ID: 19947881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.
    Weatherholtz R; Millar EV; Moulton LH; Reid R; Rudolph K; Santosham M; O'Brien KL
    Clin Infect Dis; 2010 May; 50(9):1238-46. PubMed ID: 20367225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HHS-CDC news: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--US, 1998-2003.
    Ann Pharmacother; 2005 Nov; 39(11):1967-8. PubMed ID: 16219891
    [No Abstract]   [Full Text] [Related]  

  • 16. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta.
    Leal J; Vanderkooi OG; Church DL; Macdonald J; Tyrrell GJ; Kellner JD
    Pediatr Infect Dis J; 2012 Sep; 31(9):e169-75. PubMed ID: 22673137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining invasive pneumococcal disease in the U.S. elderly.
    McBean AM; Park YT; Caldwell D; Yu X
    Vaccine; 2005 Dec; 23(48-49):5641-5. PubMed ID: 16111788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
    Millar EV; Watt JP; Bronsdon MA; Dallas J; Reid R; Santosham M; O'Brien KL
    Clin Infect Dis; 2008 Oct; 47(8):989-96. PubMed ID: 18781875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.